MedTrace Logo

Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis

NCT00004406 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.

Conditions

Interventions

DRUG

human parathyroid hormone

Sponsors & Collaborators

Principal Investigators

  • John Paul Bilezikian · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
29 Years
Max Age
67 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-10-31
Completion
2004-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004406 on ClinicalTrials.gov